Physician profile
Mary Boyte
NPI 1750756367
$4,061.05
in general payments reported to CMS, 2019-2025
48 companies · $694 in 2025
The $694 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,129 · 2022: $259 · 2023: $984 · 2024: $995 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216 · Education: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.76 |
| Education | $457.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $439.60 | 2021-2025 | Tagrisso, Enhertu, Lynparza |
| Janssen Biotech, INC. | $382.62 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $310.71 | 2021-2025 | Keytruda, Lynparza, Reblozyl |
| Incyte Corporation | $276.99 | 2021-2025 | Jakafi |
| Beigene USA, INC. | $215.02 | 2021-2024 | Brukinsa |
| Astellas Pharma US INC | $203.49 | 2021-2024 | Padcev, Vyloy |
| Amgen INC. | $179.07 | 2021-2024 | Evenity, Lumakras |
| E.R. Squibb & Sons, L.L.C. | $163.60 | 2021-2023 | Opdivo, Opdualag |
| Pharmacosmos Therapeutics INC. | $145.92 | 2024-2025 | Monoferric |
| Daiichi Sankyo INC. | $140.77 | 2023-2025 | Enhertu, Datroway |
| Geron Corporation | $137.94 | 2025 | Rytelo |
| Astellas Pharma Global Development | $124.55 | 2025 | Xtandi |
| Novartis Pharmaceuticals Corporation | $115.81 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.68 | 2021-2024 | Alunbrig |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Boyte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.